Literatur
-
1
Bhattacharya M, Peri K G, Almazan G, Ribeiro-da-Silva A, Shichi H, Durocher Y, Abramovitz M, Hou X, Varma D R, Chemtob S.
Nuclear
localization of prostaglandin E2 receptors.
Proc Natl
Acad Sci USA.
1998;
95
15 792
-
2
Dormond O, Foletti A, Paroz C, Ruegg C.
NSAIDs inhibit alpha V
beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell
spreading, migration and angiogenesis.
Nature Med.
2001;
7
1041
-
3
DuBois R N, Radhika A, Reddy B S, Entingh A J.
Increased
cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors.
Gastroenterology.
1996;
110
1259
-
4
Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N.
Up-regulation of
cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas.
Gastroenterology.
1994;
107
1183
-
5
Gupta R A, DuBois R N.
Colorectal
cancer prevention and treatment by inhibition of cyclooxygenase-2.
Nature
Cancer Reviews.
2001;
1
11
-
6
Karnes W E, Shattuck-Brandt R, Burgart L J, DuBois R N, Tester D J, Cunningham J M, Kim C Y, McDonnell S K, Schaid D J, Thibodeau S N.
Reduced
COX-2 protein in colorectal cancer with defective mismatch repair.
Cancer
Res.
1998;
58
5473
-
7
Kinzler K W, Vogelstein B.
Landscaping the cancer
terrain.
Science.
1998;
280
1036
-
8
Mann M, Sheng H, Shao J, Williams C S, Pisacane P I, Sliwkowski M X, DuBois R N.
Targeting cyclooxygenase 2 and HER-2/neu
pathways inhibits colorectal carcinoma growth.
Gastroenterology.
2001;
120
1713
-
9
Marnett L J, Kalgutkar A S.
Cyclooxygenase
2 inhibitors: discovery, selectivity and the future.
Trends
Pharmacol Sci.
1999;
20
465
-
10
Newberry R D, Stenson W F, Lorenz R G.
Cyclooxygenase-2-dependent arachidonic acid metabolites
are essential modulators of the intestinal immune response to dietary
antigen.
Nature Med.
1999;
5
900
-
11
Reuter B K, Asfaha S, Buret A, Sharkey K A, Wallace J L.
Exacerbation of inflammation-associated
colonic injury in rat through inhibition of cyclooxygenase-2.
J
Clin Invest.
1996;
98
2076
-
12
Sano H, Kawahito Y, Wilder R L, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T.
Expression of cyclooxygenase-1 and -2 in
human colorectal cancer.
Cancer Res.
1995;
55
3785
-
13
Sinicrope F A, Lemoine M, Xi L, Lynch P M, Cleary K R, Shen Y, Frazier M L.
Reduced expression of cyclooxygenase 2 proteins
in hereditary nonpolyposis colorectal cancers relative to sporadic
cancers.
Gastroenterology.
1999;
117
350
-
14
Smith W L, DeWitt D L, Garavito R M.
Cyclooxygenases: structural, cellular, and
molecular biology.
Ann Rev Biochem.
2000;
69
145
-
15
Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo M M.
Acceleration
of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta
716) knockout mice.
Nature Med.
2001;
7
1048
-
16
Steinbach G, Lynch P M, Phillips R K, Wallace M H, Hawk E, Gordon G B, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su L K, Levin B.
The effect
of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous
polyposis.
N Engl J Med.
2000;
342
1946
-
17
Thun M J, Namboodiri M M, Heath C W.
Aspirin use and reduced risk of
fatal colon cancer.
N Engl J Med.
1991;
325
1593
-
18
Torrance C J, Jackson P E, Montgomery E, Kinzler K W, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani C M.
Combinatorial chemoprevention
of intestinal neoplasia.
Nature Med.
2000;
6
1024
-
19
Williams C S, Luongo C, Radhika A, Zhang T, Lamps L W, Nanney L B, Beauchamp R D, DuBois R N.
Elevated
cyclooxygenase-2 levels in Min mouse adenomas.
Gastroenterology.
1996;
111
1134
-
20
Giardiello F M, Yang V W, Hylind L M, Krush A J, Petersen G M, Trimbath J D, Piantadosi S, Garrett E, Geimann D E, Hubbard W, Offerhaus G J, Hamilton S R.
Primary chemoprevention of familial
adenomatous polyposis with sulindac.
N Engl J Med.
2002;
346(14)
1054-9
-
21
Suleiman S, Rex D K, Sonnenberg A M.
Chemoprevention of colorectal cancer by
aspirin: a cost-effectiveness analysis.
Gastroenterology.
2002;
122(1)
78-84
-
22
Pai R, Soreghan B, Szabo I L, Pavelka M, Baatar D, Tarnawski A S.
Prostaglandin
E2 transactivates EGF receptor: a novel mechanism fpr promoting
colon cancer growth and gastrointestinal hypertrophy.
Nat
Med.
2002;
8(3)
289-93
Priv.-Doz. Dr. med. Michael Geißler
Medizinische Klinik II
Hugstetter Straße 55
79106 Freiburg
Phone: 0761/2703260
Fax: 0761/2703260
Email: mgeissl@sun11.ukl.uni-freiburg.de
